PUBLIC COMPANY
save$AMLXAmylyx Pharmaceuticals, Inc.
$AMLX29.17-0.38%Cambridge, MA, USupdated 10h ago
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.
community read0 votes
pipeline
3
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 11Phase 21Phase 3
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- —An Expanded Access Protocol to Provide Avexitide in Patients With Post-Bariatric Hypoglycemia
- phase1AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
- phase2AMX0035 in Adult Patients With Wolfram Syndrome
- phase3Avexitide for Treatment of Post-Bariatric Hypoglycemia
- phase2Open Label Extension Study of AMX0035 in Patients With ALS
- phase2Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease
- phase3Extension Study Evaluating The Safety And Tolerability of AMX0035
- phase3AMX0035 and Progressive Supranuclear Palsy
🐶 Hiring Signal
next earnings Nov 5, 2026
News
- STAT+: The biotech scorecard for the third quarter: 15 stock-moving events to watchHere is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter.stat · 3mo ago
Data sources
last refreshed 21m ago
Found something off?
comments(0)
5-min edit window · permanent after that